A phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancer

Clinical Cancer Research

Volumn 8, Issue 5, 2002, Pages 1065-1072

  Hahn, Stephen M ^a   Bernhard, Eric J ^a   Regine, William ^b   Mohiuddin, Mohammed ^b   Haller, Daniel G ^a   Stevenson, James P ^a   Smith, Debbie ^a   Pramanik, Barnali ^f   Tepper, Joel ^c   DeLaney, Thomas F ^d   Kiel, Krystina D ^e   Morrison, Briggs ^f   Deutsch, Paul ^f   Muschel, Ruth J ^a   McKenna, W Gillies ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

L 778123; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RADIOSENSITIZING AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CELL CYCLE PHASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; ESOPHAGITIS; FEMALE; GENE MUTATION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; NEUTROPENIA; ONCOGENE RAS; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RADIOSENSITIVITY;

ADULT; AGED; ALKYL AND ARYL TRANSFERASES; CARCINOMA, NON-SMALL-CELL LUNG; CELL SURVIVAL; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; FARNESYLTRANSTRANSFERASE; FEMALE; HEAD AND NECK NEOPLASMS; HEMATOLOGIC DISEASES; HUMANS; IMIDAZOLES; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOUTH MUCOSA; NAUSEA; SKIN DISEASES; STOMATITIS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; VOMITING;

EID: 0036097103     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. The hallmarks of cancer
2. The role of the H-ras oncogene in radiation resistance and metastasis
3. Ras oncogenes in human cancer: A review
4. The ras oncogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation
5. Oncogene-transformed NIH 3T3 cells display radiation resistance levels indicative of a signal transduction pathway leading to the radiation resistant phenotype
6. Synergistic effect of the v-myc oncogene with H-ras on radioresistance
7. 2 delay in radiation-resistant cells obtained by transformation of primary rat embryo cells with the oncogenes H-ras and v-myc
8. Increased radioresistance of EJras-transformed human osteosarcoma cells and its modulation by lovastatin, an inhibitor of p21ras isoprenylation
9. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development
10. Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation
11. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity
12. Protein prenylation: Molecular mechanisms and functional consequences
13. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to Taxol and epothilones
14. Benzodiazepine peptidomimetics: Potent inhibitors of Ras farnesylation in animal cells
15. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice
16. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts
17. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts
18. Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes
19. Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated H-ras
20. The farnesyl protein transferase (FPTase) inhibitor L-778,123 in patients with solid cancer
21. Phase I trial of the farnesyl protein transferase (FPTase) inhibitor L-778,123 on a 14- or 28-day dosing schedule
22. Hypoxic fractions of solid tumors: Experimental techniques, methods of analysis, and a survey of existing data
23. Intrinsic radiosensitivity and prediction of patient response to radiotherapy for carcinoma of the cervix
24. Effect of antisense c-raf-1 on tumorigenicity and radiation sensitivity of a human squamous carcinoma
25. Apoptosis induced at different dose rates: Implication for the shoulder region of cell survival curves
26. raf involvement in the simultaneous genetic transfer of the radioresistant and transforming phenotypes
27. Differences in effects of oncogenes on resistance of γ rays, ultraviolet light, and heat shock
28. 2 delay
29. Improved survival in stage III non-small cell lung cancer: Seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 Trial
30. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary results of a Phase III trial in regionally advanced, unresectable non-small cell lung cancer
31. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer
32. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized intergroup study 0099
33. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus
34. Concurrent chemoradiation in unresectable stage III non-small cell lung cancer: Too much pain for no gain
35. Long-term survival results for patients with locally advanced, initially unresectable non-small cell lung cancer treated with aggressive concurrent chemoradiation
36. Phase I study of docetaxel with concomitant thoracic radiation therapy
37. Predictors of severe esophagitis include use of concurrent chemotherapy, but not the length of irradiated esophagus: A multivariate analysis of patients with lung cancer treated with nonoperative therapy
38. Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2
39. Overexpression of the Ras-related TC21/R-Ras2 protein may contribute to the development of human breast cancers
40. Aberrant function of the Ras signal transduction pathway in human breast cancer
41. Proliferation of human malignant astrocytomas is dependent on Ras activation
42. Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with p activity
43. Non-ras targets of farnesyltransferase inhibitors: Focus on p.
44. Cell-cycle-dependent activation of mitogen-activated protein kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling
45. 1 pause in sensitive human tumor cell lines